BDSX BIODESIX INC
Services-Medical Laboratories · Nasdaq · SEC CIK 1439725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.2%
TTM net income YoY31.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-18.7%
Net margin-25.7%
FCF margin-18.1%
EBITDA margin-13.4%
Returns
ROE-778.9%
ROA-29.6%
ROIC (approx.)-50.2%
Asset turnover1.15x
Leverage & solvency
Liabilities / assets90.8%
Debt / equity5.76x
Current ratio2.96x
Interest coverage-2.45x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.04M | $26.86M | $25.55M | $28.75M | $21.77M | $20.02M | $17.96M | $20.43M |
| R&D expense | $2.99M | $3.13M | $3.29M | $2.87M | $2.99M | $3.27M | $2.87M | $2.41M |
| SG&A expense | $22.50M | $24.28M | $24.26M | $22.97M | $21.71M | $22.41M | $20.45M | $20.22M |
| Operating income | -$6.11M | -$5.39M | -$6.20M | -$1.97M | -$7.05M | -$9.72M | -$9.14M | -$6.65M |
| Interest expense | $2.00M | $1.98M | $1.98M | $2.06M | $2.07M | $1.90M | $1.69M | $1.75M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.03M | -$7.27M | -$7.79M | -$3.98M | -$8.72M | -$11.47M | -$11.10M | -$8.25M |
| EBITDA | -$4.71M | -$4.00M | -$4.80M | -$580,000 | -$5.64M | -$8.28M | -$7.70M | -$5.20M |
| EPS (basic) | -0.75 | -0.71 | -0.81 | — | -1.16 | -1.56 | -1.52 | — |
| EPS (diluted) | -0.75 | -0.71 | -0.81 | — | -1.16 | -1.56 | -1.52 | — |
| Weighted avg. shares (diluted) | 10.66M | 10.30M | 9.66M | — | 7.50M | 7.33M | 7.30M | — |
| Banking | ||||||||
| Provision for credit losses | $196,000 | $92,000 | $24,000 | $71,000 | $0 | $8,000 | $101,000 | $434,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $28.41M | $30.00M | $25.57M | $18.99M | $16.69M | $20.82M | $17.69M | $26.33M |
| Receivables | $9.12M | $9.11M | $9.50M | $9.04M | $12.67M | $7.45M | $7.64M | $8.60M |
| Current assets | $42.13M | $43.56M | $40.91M | $32.52M | $33.40M | $32.45M | $29.62M | $39.48M |
| PP&E, net | $23.62M | $23.80M | $24.19M | $24.82M | $25.46M | $26.14M | $26.97M | $27.83M |
| Goodwill | $15.03M | $15.03M | $15.03M | $15.03M | $15.03M | $15.03M | $15.03M | $15.03M |
| Intangibles | $2.53M | $2.98M | $3.45M | $3.88M | $4.38M | $4.87M | $5.36M | $5.87M |
| Total assets | $93.94M | $95.33M | $94.64M | $87.48M | $88.72M | $87.74M | $86.24M | $97.24M |
| Current liabilities | $14.25M | $15.29M | $14.49M | $17.44M | $18.15M | $15.16M | $13.32M | $14.32M |
| Long-term debt | $50.00M | $50.00M | $50.00M | $50.01M | $50.01M | $50.02M | $40.02M | $40.03M |
| Total debt | $50.00M | $50.00M | $50.00M | $50.01M | $50.01M | $50.02M | $40.02M | $40.03M |
| Total liabilities | $85.27M | $86.18M | $85.50M | $89.94M | $90.44M | $86.60M | $75.18M | $76.37M |
| Shareholders' equity | $8.68M | $9.14M | $9.13M | -$2.46M | -$1.72M | $1.14M | $11.06M | $20.88M |
| Net debt | $21.59M | $20.00M | $24.43M | $31.02M | $33.32M | $29.20M | $22.33M | $13.69M |
| Shares outstanding | 11.05M | 10.55M | 10.11M | 8.25M | 7.95M | 146.58M | 146.44M | 7.27M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.20M | -$1.56M | -$10.17M | $778,000 | -$8.88M | -$6.57M | -$8.60M | -$4.10M |
| Capital expenditure | $555,000 | $197,000 | $81,000 | $86,000 | $48,000 | $51,000 | $74,000 | $839,000 |
| Free cash flow | -$7.76M | -$1.76M | -$10.25M | $692,000 | -$8.93M | -$6.62M | -$8.68M | -$4.93M |
| Investing cash flow | -$600,000 | -$254,000 | -$144,000 | -$104,000 | -$67,000 | -$95,000 | -$137,000 | -$884,000 |
| Financing cash flow | $6.22M | $6.24M | $16.90M | $1.71M | $4.82M | $9.79M | $97,000 | -$181,000 |
| Depreciation & amortization | $1.40M | $1.39M | $1.40M | $1.39M | $1.41M | $1.44M | $1.44M | $1.45M |
| Stock-based compensation | $852,000 | $820,000 | $1.11M | $1.07M | $1.05M | $1.04M | $972,000 | $1.26M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.